ClinicalTrials.gg
Not yet recruitingNCT05049603STAGO-2Updated Mar 15, 2023

A Randomized Clinical Trial to Evaluate the Effects of Atorvastatin on Graves' Orbitopathy (GO): the STAGO-2 Study

A Phase 3 interventional study of Atorvastatin 20mg and Placebo in Graves' Orbitopathy, sponsored by University of Pisa. Not yet recruiting at 1 site in Italy. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-03-15.

Sponsored by University of Pisa · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Graves Ophthalmopathy by University of Pisa — 4 open to participants now, 4 under way, 2 of them phase 3. Graves Ophthalmopathy · University of Pisa.

Started
2024
with 1 other
Phase 3
2 of 11
2 open now
Registered
10th of 11
by date

Among the 11 studies in Graves Ophthalmopathy by University of Pisa, this one is one of 2 that started in 2024, is one of 2 in phase 3, and was the 10th registered.

Graves Ophthalmopathy

200 studies on the registry are indexed under Graves Ophthalmopathy; 59 are open to participants now.

Browse Graves Ophthalmopathy studies →

Open to participants now

4 of the 11 studies in Graves Ophthalmopathy by University of Pisa are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 39 Graves Ophthalmopathy studies recruiting now, 8 (21%) set no upper age limit and 17 (44%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Graves Ophthalmopathy by University of Pisa, or all of them as a file.
02

Study summary

Graves' orbitopathy (GO) is the most common extra-thyroidal manifestation of Graves' disease (GD). Based on its clinical signs and symptoms, GO is graded as mild, moderate-to-severe, or severe, and active or inactive, the latter feature being established on a 5/7-scale score named Clinical Activity Score (CAS).

The European Group on Graves Orbitopathy (EUGOGO) has recently formulated and published up-to-date guidelines for the management of GO, according to which high dose intravenous (iv) glucocorticoids (GC) (ivGC) is the first line treatment for moderate-to-severe and active GO. A protective effect of atorvastatin on the development of GO in patients with GD has been reported, based on which we recently conducted a phase II, randomized, open label clinical trial and found that atorvastatin improves the response of GO to ivGCs in hypercholesterolemic patients. The effect was unrelated to cholesterol levels, suggesting that it may be the consequence of a direct action of atorvastatin. To investigate this issue further and to introduce atorvastatin in the clinical practice, we designed the present Phase III, double-blinded, multicenter, randomized, adaptive, superiority, no profit, clinical trial to evaluate the effects of atorvastatin on Graves' Orbitopathy (GO) in patients with moderate-to-severe and active GO subjected to intravenous glucocorticoid therapy, regardless of cholesterol levels.

Read the detailed description

Graves' orbitopathy (GO) is the most common extra-thyroidal manifestation of Graves' disease (GD). GO profoundly impairs the quality of life of affected patients. The pathogenesis is autoimmune, reflecting cross-reactivity against antigens shared by thyroid epithelial cells and orbital fibroblasts. Once the autoimmune reaction is initiated, a series of molecular mechanisms involving T and B cells, antibodies, cytokines, and oxidative stress, lead to fibroblast proliferation and release of glycosaminoglycans, resulting in the clinical manifestations of the disease, namely exophthalmos (or proptosis), soft tissue inflammation, diplopia, and in the most severe cases sight reduction or loss, due to corneal damage or to compression of the optic nerves, the so called optic neuropathy. Based on its clinical signs and symptoms, GO is graded as mild, moderate-to-severe, or severe, and active or inactive, the latter feature being established on a 5/7-scale score named Clinical Activity Score (CAS).

The European Group on Graves Orbitopathy (EUGOGO), a scientific Society involving several European Centers, including some of the Centers participating in the present study, has formulated and published up-to-date guidelines for the management of GO, which is referred to across the present study protocol.

According to EUGOGO guidelines, high dose intravenous (iv) glucocorticoids (GC) (ivGC) is the first line treatment for moderate-to-severe and active GO. The use of systemic glucocorticoids takes advantage from their immunosuppressive and anti-inflammatory actions, resulting in an overall beneficial effect ranging from \~35 to \~60% of patients in various studies. Recent studies have provided evidence for the best balance in terms of effectiveness/risks for a total methylprednisolone dose of 4.5 g, given in 12 weekly administrations, six of 500 and six of 250 mg, which is therefore recommended.

Besides genetic and demographical variables, risk factors associated with the development of GO in GD patients are known to be inadequate control of hyperthyroidism, radioiodine treatment, and smoking. In a large retrospective study conducted in more than 8,000 individuals with GD, it was reported that treatment with 3-hydroxy-3-methylglutaryl-coenzyme reductase inhibitors, better known as statins, especially atorvastatin, is associated with a \~40% reduced risk of developing GO in GD patients. The findings were interpreted as the consequence of the anti-inflammatory action of statins, being GO an autoimmune, inflammatory condition. Statins influence autophagic events and it has been shown that they induce cell death of human fibroblasts through a complex mechanism involving co-regulation of apoptosis, autophagy, and unfolded protein response (UPR). Thus, statins may reduce GO risk by modulating both apoptosis and autophagy activities. The molecular mechanisms that determine autophagy, apoptosis, and their interaction are not fully established, but the impact of statins on these two processes and their interplay in different cell types may provide a novel explanation for their pleiotropic effects in GO. Shih et al. found a positive correlation between macrophage count in the Muller's muscle and severity of upper lid retraction and concluded that the degree of inflammatory cell infiltration of Muller's muscle is associated with clinical severity of upper eyelid retraction in GO. Because some statins potently affect macrophage viability in vitro through the induction of apoptotic process, it is plausible that the early autophagic flux induced by statin treatment may be a potential mechanism to induce apoptosis of Muller's muscle infiltrating macrophages in patients with GO, thus eliciting a beneficial effect.

In addition to a possible direct action of statins on the eye, the possibility exists that the action of statins in GO may additionally reflect lowering of cholesterol. Thus, in a recent cross-sectional study a direct correlation between total and LDL-cholesterol levels and the presence and activity of GO in unselected patients with a GD of recent onset was observed, suggesting a direct link between cholesterol and GO. In addition, LDL-cholesterol was found to be a predictor of response to treatment. The mechanisms responsible for the relation between the presence of GO and cholesterol may be related to the altered inflammatory state of hypercholesterolemia. Thus, it is well known that disorders of lipid metabolism are associated with a state of mild-to-moderate, systemic, chronic inflammation. The increase load of free fatty acids on the liver, present in hyperlipemic states, causes dysfunction of the mitochondria and endoplasmic reticulum of hepatocytes, leading to the release of reactive oxygen radical species. In addition, free fatty acid can indirectly cause the release of pro-inflammatory cytokines, namely interleukin-6 and tumor necrosis factor-α, both involved in the pathogenetic mechanisms of GO.

Based on these findings, the investigators recently conducted a phase II, randomized, open label, external ophthalmological investigator-blinded, pilot, clinical trial, to determine whether administration of statins increases the efficacy of ivGC in patients with moderate-to-severe, active GO. Atorvastatin improved the response of GO to ivGCs in hypercholesterolemic patients. The effect was unrelated to cholesterol levels, suggesting that it may be the consequence of a direct action of atorvastatin. To investigate this issue further and to introduce atorvastatin in the clinical practice, the present Phase III, double-blinded, multicenter, randomized, adaptive, superiority, no profit, clinical trial was designed to evaluate the effects of atorvastatin on Graves' Orbitopathy (GO) in patients with moderate-to-severe and active GO subjected to intravenous glucocorticoid therapy, regardless of cholesterol levels.

03

Conditions studied

  • Graves' Orbitopathy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients willing and capable of giving written , which includes compliance with the requirements and restrictions listed in the consent form
  2. A diagnosis of Graves' disease based on the presence of hyperthyroidism associated with detectable anti-thyrotropic hormone (TSH) receptor autoantibodies (TRAb). Patients must be euthyroid under control on stable medical regimen and every effort will be made to maintain the euthyroid status for the entire duration of the clinical trial
  3. A moderate-to-severe GO, defined as the presence of at least one of the following criteria: an exophthalmos ≥2 mm compared with normal values for sex and race; presence of inconstant to constant diplopia; a lid retraction ≥2 mm, lasting since no longer than 9 months
  4. Active GO: CAS (4) ≥ 3 out of 5 points in the most affected eye
  5. Male and female patients of age: 18-75 years
  6. , ALT and CPK levels ≤ 3 times the upper value of normal range
  7. Women of (WOCBP, namely not in menopause or in menopause since less than two years; in all other instances women will be considered as non-WOCBP) and men who are sexually active with WOCBP must use any method with a failure rate of less than 1% per year (as indicated in Appendix) for at least 6 and 7,5 months, respectively, after the last dose of the drug (see also 2014_09_HMA_CTFG_Contraception.pdf, namely the "2014 CTFG Reccommendtions related to contraception and pregnancy testing in clinical trials").
  8. Compliant patient, regular follow-up possible

Exclusion criteria

Exclusion Criteria

  1. Optic neuropathy
  2. or treatment for GO in the last 3 months. Use of selenium in the last 3 months or during the clinical trial
  3. Previous surgical or radiant (orbital irradiation) treatment for GO
  4. Radioiodine treatment for hyperthyroidism over the last 3 months, as it can affect GO (4)
  5. Statin treatment in the last 3 months
  6. to GC: to the active substance or to any of the ; uncontrolled hypertension, uncontrolled diabetes; history of peptic ulcer; urinary infections, glaucoma, systemic fungal infections, systemic infections unless appropriate therapy is employed, idiopathic thrombocytopenic purpura, cerebral edema associated with malaria. Use of medications interfering with GC or increasing the risk of GC-related adverse events (see prohibited therapies)
  7. Pregnant or lactating females as determined by positive serum or urine HCG test at baseline
  8. Acute or chronic liver disease
  9. All factors that could increase the risk of rhabdomyolysis, in particular medications that could increase this risk (see prohibited therapies)
  10. Contraindications to statins, namely: hypersensitivity to atorvastatin or other statins, or hypersensitivity or intolerance to the medication excipients such as lactose; current or past liver diseases; alterations of liver tests.
  11. Medications interfering/interacting with statins (see prohibited therapies)
  12. Relevant
  13. Recent (≤1 year) history of alcoholism or drug abuse
  14. Mental illness that prevent patients from comprehensive, written
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
102 participants (estimated)

Study arms

  • Experimental
    Atorvastatin

    Atorvastatin 20 mg/day (the experimental treatment), one tablet/day, given approximately at 10 pm, after dinner and before going to bed, for 24 weeks, associated with intravenous methylprednisolone pulse therapy (the standard treatment), given over a period of 12 weeks

    Drug: Atorvastatin 20mg

  • Placebo comparator
    Placebo

    Intravenous methylprednisolone pulse therapy (the standard treatment), given over a period of 12 weeks, and placebo (one tablet/day, given approximately at 10 pm, after dinner and before going to bed) for 24 weeks

    Other: Placebo

Interventions

  • DrugAtorvastatinStudies of AtorvastatinAtorvastatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    One tablet/day, given approximately at 10 pm, after dinner and before going to bed, for 24 weeks

    Also known as: Study Group

  • OtherPlacebo

    One tablet/day, given approximately at 10 pm, after dinner and before going to bed, for 24 weeks

    Also known as: Placebo group

06

What researchers measure

Primary outcomes

  1. Outcome of GO

    Comparison of overall GO outcome determined using a composite evaluation (% of responders). Response is defined as change in two outcome measures in at least one eye, without deterioration in any of the same measures in both eyes (compared to baseline): Patients meeting the improvement criteria will be considered as "responders". All other patients will be considered as "non-responders".

    Time frame: 24 weeks

Secondary outcomes

  1. Outcome of GO

    Comparison of overall GO outcome determined using a composite evaluation (% of responders). Response is defined as change in two outcome measures in at least one eye, without deterioration in any of the same measures in both eyes (compared to baseline): Patients meeting the improvement criteria will be considered as "responders". All other patients will be considered as "non-responders".

    Time frame: 12 weeks

  2. Outcome of GO

    Comparison of overall GO outcome determined using a composite evaluation (% of responders). Response is defined as change in two outcome measures in at least one eye, without deterioration in any of the same measures in both eyes (compared to baseline): Patients meeting the improvement criteria will be considered as "responders". All other patients will be considered as "non-responders".

    Time frame: 48 weeks

  3. Quality of life (comparison between the two groups)

    Quality of life (QoL) will be evaluated using the GO QoL questionnaire (GO-QoL). Questionnaire consists of two subscales: 1) visual functioning (eight questions concerning limitations attributable to decreased visual acuity, diplopia, or both), and 2) appearance (eight questions referring to limitations in psychosocial functioning attributable to changes in appearance). Questions are scored as severely limited (one point), a little limited (two points), or not limited at all (three points). The two scores (8-24 points) are summed into a total score. A higher score means a better QoL. The total score and the subscores will be compared between the two groups

    Time frame: 12 weeks

  4. Quality of life (comparison between the two groups)

    Quality of life (QoL) will be evaluated using the GO QoL questionnaire (GO-QoL). Questionnaire consists of two subscales: 1) visual functioning (eight questions concerning limitations attributable to decreased visual acuity, diplopia, or both), and 2) appearance (eight questions referring to limitations in psychosocial functioning attributable to changes in appearance). Questions are scored as severely limited (one point), a little limited (two points), or not limited at all (three points). The two scores (8-24 points) are summed into a total score. A higher score means a better QoL. The total score and the subscores will be compared between the two groups

    Time frame: 24 weeks

  5. Quality of life (comparison between the two groups)

    Quality of life (QoL) will be evaluated using the GO QoL questionnaire (GO-QoL). Questionnaire consists of two subscales: 1) visual functioning (eight questions concerning limitations attributable to decreased visual acuity, diplopia, or both), and 2) appearance (eight questions referring to limitations in psychosocial functioning attributable to changes in appearance). Questions are scored as severely limited (one point), a little limited (two points), or not limited at all (three points). The two scores (8-24 points) are summed into a total score. A higher score means a better QoL. The total score and the subscores will be compared between the two groups

    Time frame: 48 weeks

  6. GO relapse

    Worsening in comparison with the 12 week evaluation (% of relapse) Worsening is defined as change in two outcome measures in at least one eye (compared to 12 week):

    Time frame: 24 weeks

  7. GO relapse

    Worsening in comparison with the 12 week evaluation (% of relapse) Worsening is defined as change in two outcome measures in at least one eye (compared to 12 week):

    Time frame: 48 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2024; primary completion for Dec 2025, 23 months later.

Of 29 phase 3 interventional studies under Graves Ophthalmopathy, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 25. This study's planned 23 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2021
First posted
Sep 20, 2021
StartEst.
Jan 1, 2024
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2026
Last update
Mar 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05049603
Lead sponsor
University of Pisa
Collaborators
Università degli Studi dell'Insubria, University of Catania, University of Messina
Responsible party
Marinò Michele (Associate Professor, University of Pisa) — Principal investigator
First posted
Sep 20, 2021
Start date
Jan 1, 2024 (estimated)
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Mar 15, 2023

Study contacts

Michele Marinò, MD
Contact
michele.marino@med.unipi.it
+39050997346
Giulia Lanzolla, MD
Contact
giulia.lanzolla8@gmail.com
+393407685085

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atorvastatin

Start the discussion